Last reviewed · How we verify
Farydak (PANOBINOSTAT)
At a glance
| Generic name | PANOBINOSTAT |
|---|---|
| Sponsor | Secura |
| Drug class | Histone Deacetylase Inhibitor |
| Target | Histone deacetylase 4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 2015 |
Approved indications
- Multiple myeloma
- Primary cutaneous T-cell lymphoma
Common side effects
- Diarrhea
- Fatigue
- Nausea
- Peripheral edema
- Decreased appetite
- Pyrexia
- Vomiting
- Thrombocytopenia
- Lymphopenia
- Leukopenia
- Neutropenia
- Anemia
Serious adverse events
- Pneumonia
- Diarrhea
- Thrombocytopenia
- Fatigue
- Sepsis
- Death
- Infection
- Hemorrhage
Drug interactions
- CYP2D6 Substrates
Key clinical trials
- CINC424A2X01B Rollover Protocol (PHASE4)
- Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease (PHASE1)
- Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) (PHASE1)
- Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors (PHASE1)
- Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors (PHASE1)
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma (PHASE2)
- Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent Medulloblastoma (EARLY_PHASE1)
- A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Farydak CI brief — competitive landscape report
- Farydak updates RSS · CI watch RSS
- Secura portfolio CI